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Ventricular enlargement and reduced prefrontal volume are
consistent findings in schizophrenia. Both are present in first
episode subjects and may be detectable before the onset of
clinical disorder. Substance misuse is more common in peo-
ple with schizophrenia and is associated with similar brain
abnormalities. We employ a prospective cohort study with
nested case control comparison design to investigate the as-
sociation between substance misuse, brain abnormality, and
subsequent schizophrenia. Substance misuse history, imag-
ing data, and clinical information were collected on 147 sub-
jects at high risk of schizophrenia and 36 controls. Regions
exhibiting a significant relationship between level of use of
alcohol, cannabis or tobacco, and structure volume were
identified. Multivariate regression then elucidated the rela-
tionship between level of substance use and structure volumes
while accounting for correlations between these variables
and correcting for potential confounders. Finally, we estab-
lished whether substance misuse was associated with later
risk of schizophrenia. Increased ventricular volume was as-
sociated with alcohol and cannabis use in a dose-dependent
manner. Alcohol consumption was associated with reduced
frontal lobe volume.Multiple regression analyses found both
alcohol and cannabis were significant predictors of these ab-
normalities when simultaneously entered into the statistical
model. Alcohol and cannabis misuse were associated with an
increased subsequent risk of schizophrenia. We provide pro-
spective evidence that use of cannabis or alcohol by people at
high genetic risk of schizophrenia is associated with brain
abnormalities and later risk of psychosis. A family history
of schizophrenia may render the brain particularly sensitive
to the risk-modifying effects of these substances.
Key words: alcohol/cannabis/familial/psychosis/imaging
Introduction
Schizophrenia is associated with structural brain abnor-
malities.1 Many of these abnormalities precede the devel-
opment of illness in people who later become unwell and
cannot simply be attributed to antipsychotic medication.2
However, besides familial factors,3 the reasons for the de-
velopment of schizophrenia and its associated structural
abnormalities are far from clear. Environmental factors
account for a significant proportion of the risk for schizo-
phrenia, may account for structural magnetic resonance
imaging (MRI) changes, and their modification may of-
fer opportunities for primary prevention.
Schizophrenia is strongly associated with substance
use, the 3 most commonly abused substances being alco-
hol, tobacco, and cannabis.4,5 For some substances, this
relationship may be causal, the evidence being most
robust for cannabis.6–8 A causative link between alcohol
and schizophrenia has also been proposed.9 There is how-
ever a dearth of prospective studies investigating this pu-
tative association, which could potentially be further
obscured by the practice of characterizing those with
a history of heavy drinking and a chronic psychosis as
having alcoholic hallucinosis.
In common with schizophrenia, misuse of some
substances has been associated with brain structural
abnormalities. These have been best characterized for
alcoholism; generalized brain tissue loss, lateral ventricular
enlargement, and prefrontal cortex deficits have been re-
peatedly observed;10–12 and medial temporal lobe volume
loss also reported.13–15 Evidence associating cannabis use
with brain structural abnormalities in healthy control sub-
jects is less convincing, 2 recent reviews finding no consis-
tent structural imaging findings.16,17
In schizophrenia, the brain structural abnormalities
may precede illness and be a marker of risk,2 whereas
in alcoholism, they are generally regarded as being a
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consequence of repeated substance use.12,18 Despite these
differences, comparison of the nature of the deficits
observed in the 2 conditions reveals considerable overlap,
only superior anterior temporal lobe volume loss being
greater in schizophrenic than alcohol-dependent sub-
jects.19 In keeping with this, individuals with both condi-
tions exhibit compounded abnormalities, volume loss
being greater in comorbid individuals than those with
either condition alone.20 In contrast to the negative
findings in healthy subjects, individuals with schizophre-
nia who use cannabis also exhibit exaggerated structural
abnormalities, more pronounced gray matter loss being
demonstrated when compared with noncannabis using
schizophrenic control subjects.21,22
Thus, people with schizophrenia may have a particular
sensitivity to brain tissue loss on exposure to either alco-
hol or cannabis. If this susceptibility is present prior to
illness being diagnosed, then substance misuse by individ-
uals at elevated risk of schizophrenia may be associated
with detectable structural abnormalities. Indeed, this
may be so even when the cumulative quantities of sub-
stances consumed is considerably less than in studies
demonstrating the brain structural consequences of
habitual substance use in nonschizophrenic populations.
Examining whether substance misuse is associated
with structural brain abnormalities in people who are
well but at risk of schizophrenia is, as yet, untested. If
such a link were established, it could provide evidence
that people at genetically high risk of schizophrenia
are indeed particularly vulnerable to the brain structural
consequences of substance misuse. This would have
obvious ramifications for the interpretation of the struc-
tural imaging abnormalities observed in established
schizophrenia. If, however, use of these substances was
also associated with the subsequent development of
schizophrenia, the implications of such findings could
be potentially even further reaching. It would suggest
that these brain structural changes actually reflected pro-
cesses by which substance use increases the risk of sub-
sequently developing of schizophrenia.
Investigation of these possibilities requires a prospective
study of subjects who are scanned when well and
then followed up until a sufficient proportion develop
schizophrenia. Such a design enables exploration of the re-
lationship between level of exposure to various substances
and both volumes of structures of particular interest
(namely, the ventricles, frontal lobes, amygdala-hippo-
campal complex [AHC], and thalami) and risk of subse-
quently developing schizophrenia. The Edinburgh High-
Risk Study (EHRS) provides exactly this opportunity.
Methods
Participants and Assessments
Data were collected on people at elevated risk of schizo-
phrenia as part of the EHRS. Details of this recruitment
process have been described previously.23,24 In brief, indi-
viduals with schizophrenia, with a family history of
schizophrenia, and with adolescent relatives were identi-
fied from psychiatric hospital case records. We then
approached their relatives, and the 150 high-risk subjects
aged 16–25 years who agreed to participate were given
a detailed clinical, neuropsychological, and brain imaging
assessment. A control group of 36 subjects, without a fam-
ily history of schizophrenia, were also recruited from the
same areas of the country as the high-risk subjects.
At entry into the study, as one of this battery of assess-
ments, lifetime highest level of use of various drugs was
ascertained by self-report in face-to-face interviews. Level
of use was then categorized for each substance, category
cutoffs being assigned as appropriate for each of the sub-
stances in question. These cutoffs are detailed in table 1
for alcohol, cannabis, and tobacco. For alcohol, a low-
use category of 3 units/wk was chosen to enable sepa-
ration of none-teetotal but occasional users from those
consuming alcohol more regularly. As we speculated
that high-risk individuals may be particularly susceptible
to the brain structural consequences of alcohol, we be-
lieved separation of these 2 groups to be particularly im-
portant. The latter group could contain individuals using
considerable quantities of alcohol, and this could be even
more of an issue if there were any underreporting of
alcohol consumption. In the case of ecstasy, amphet-
amines, and LSD, the categories of use employed were
never, isolated (use on a maximum of 3 occasions),
repeated (use >3 occasions but less than monthly), and
frequent (use at a level greater than once a month). Mem-
bers of the control group were also examined as above.
As described previously,25 both the high-risk and con-
trol subjects were followed up at regular intervals during
the course of the study, which ran until 2004. Present
State Examination ratings were obtained at each point
of follow-up and after diagnosis in subjects who became
ill. This report utilizes only the baseline imaging and
clinical data, together with rates of development of
schizophrenia during the entire study.
MRI Scanning and Analysis
Each participant underwent MRI scanning on a 1-T Sie-
mens (Erlangen, Germany) Magnetom scanner. Details
of image acquisition and processing have been given else-
where.26
Image processing used the software package Analyze
(Mayo Foundation, Rochester, MN) to outline neuroan-
atomical structures and ascertain their volumes.26 The
volumes of structures with preexisting evidence of struc-
tural abnormalities secondary to substance use were in-
cluded in this analysis. Structures selected were the lateral
ventricles, third ventricle, fourth ventricle, right and left
prefrontal lobes, AHC, and thalamic nuclei. The prefron-
tal, temporal, and AHC volumes were defined according
Substance Misuse in High Risk for Schizophrenia
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to standard criteria,27,28 and the remaining regions of
interest were outlined by naturalistic boundaries,
described in previous studies.26,29
Volumetric image processing was done by 3 investiga-
tors, who examined all the brain regions above on 5
brains to ensure reliability between raters (mean correla-
tion coefficient = 0.94 [range = 0.78–0.99]).
Statistical Analysis
Statistical testing was conducted with the Statistical Pro-
gram for the Social Sciences 14. Demographics were com-
pared between high-risk subgroups with different levels
of exposure to the various substances with analysis of
variance and the v2 test.
The relationship between substance use and structure
volumes was explored in 2 steps: firstly, investigation of
a dose-dependent relationship and subsequently by mul-
tiple regression analysis. This 2-step analysis was re-
quired because of the potential collinearity between
both the levels of different substances used by individuals
and the effects of the various substances on structure
volumes. Multiple regression has the potential to clarify
which relationships do exist, while accounting for poten-
tial confounders. The multiple regression analysis fo-
cused on structures that had already demonstrated
a significant dose-response relationship between volume
and level of substance use.
As level of substance use was ascertained using ordinal
measures, Spearman’s test was used for the first step, with
separate analyses being performed for each substance
and each region of interest. These analyses were under-
taken for both high-risk and control subjects. The
Table 1. Demographic Details of High-Risk Subjects in Each of the Substance Exposure Categories
Alcohol
Level of Exposurea Teetotal Occasional Regular Exceed Safe Limits Dependence P
Number of subjects (%) 10 (7.1) 28 (20) 56 (40) 37 (26) 9 (6.4)
Mean age in y (SD) 20.9 (2.3) 19.8 (3.2) 21.4 (2.8) 21.9 (2.8) 21.2 (2.9) .05
Gender (M:F) 4:6 14:14 29:27 18:19 7:2 .53
Handedness (R:L:both) 10:0:0 23:4:1 51:2:3 32:2:1 7:0:2 .16
Mean IQ (SD) 100.9 (16.9) 104.0 (16.0) 98.4 (12.2) 94.9 (9.4) 94.3 (8.9) .06
Cannabis
Level of Exposureb Nil Isolated Occasional Frequent Most days P
Number of subjects (%) 50 (35.2) 23 (16.2) 26 (18.3) 15 (10.6) 28 (19.7)
Mean age in y (SD) 21.1 (3.0) 21.5 (3.3) 21.7 (2.5) 20.6 (2.5) 21.0 (2.9) .77
Gender (M:F) 20:30 11:12 15:11 8:7 20:8 .11
Handedness (R:L:both) 42:5:2 22:0:1 24:1:1 13:1:0 23:2:3 .65
Mean IQ (SD) 98.4 (14.3) 101.8 (13.9) 100.1 (12.8) 96.6 (7.0) 95.3 (11.1) .41
Tobacco
Level of Exposurec Nil 0–10 11–20 21þ P
Number of subjects (%) 62 (45.3) 42 (30.7) 20 (14.6) 13 (9.5)
Mean age in y (SD) 21.4 (3.1) 20.6 (2.5) 21.0 (3.0) 22.5 (2.7) .20
Gender (M:F) 32:30 24:18 10:10 7:6 .94
Handedness (R:L:both) 55:5:2 37:3:1 16:1:2 12:0:1 .72
Mean IQ (SD) 102.1 (13.6) 95.3 (9.3) 101.6 (12.6) 89.8 (8.4) <.01
Note: M, male; F, female; R, right; L, left.
aExposure categories, based on highest level of consumption of alcohol during period of maximal use, are as follows: teetotal = no
history of alcohol use; occasional = use never exceeded approximately 3 U/wk; regular = regular use but not exceeding 14 U/wk for
women or 21 U/wk for men; exceed safe limits = exceeding safe recommendations; dependence = history alcohol dependence.
bExposure categories, based on highest level of exposure to cannabis during period of maximal use, are as follows: nil = never used
cannabis; isolated = used on maximum of 3 occasions; occasional = regular use but less than monthly; frequently = use of cannabis
monthly or greater; most days = use of cannabis more than 3 days a week.
cLevel of tobacco use: number of cigarettes (or equivalent) per day.
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significance of differences between R values in the high-
risk and control groups was then determined by Fisher’s
Z test.
Multiple regression analysis employed a backward
elimination model, with the independent variables of
interest allotted to 6 separate blocks. These blocks
were gender, age, whole-brain volume, alcohol use,
cannabis use, and tobacco use. Gender was entered as
a binary variable and age and whole-brain volume as con-
tinuous variables. In the blocks representing exposure to
each of the substances, levels of use were represented as
dummy variables in relation to a reference group. In the
case of cannabis and cigarettes, the reference group was
no use ever. As there were only 10 teetotal subjects (and
their characteristics were not in keeping with the general
trends seen with increasing levels of alcohol use), for
alcohol the reference group was occasional use. Separate
multiple regression analyses were performed for each
brain region that had demonstrated a significant dose
response relationship with at least one substance. In
each case, the brain structure was entered as the depen-
dent variable. Analysis was repeated with current IQ
(measured using the Wechsler Adult Intelligence Scale
Revised)30 as an additional block. Due to low subject
numbers, the multiple regression analyses were not
undertaken in the control group.
A number of the high-risk subjects had used illicit
drugs other than cannabis. Regression analysis was
therefore repeated again, excluding any individuals
with a history of dependence on any substance other
than alcohol, cannabis, or tobacco. As excluding subjects
with any level of exposure to illicit drugs other than can-
nabis would have resulted in too great a loss of statistical
power, it was not feasible to repeat regression analysis
without these subjects. A supplementary regression anal-
ysis was therefore run including level of past use of
ecstasy, amphetamines, and LSD as additional regres-
sion blocks.
In common with other studies, the distribution of ven-
tricular volumes showed a right sided skew.31 These data
were therefore log transformed prior to the regression
analysis. Subsequent standardized residuals were
checked for normality.
The v2 test or likelihood ratios (where sample size
was small) were used to compare numbers developing
schizophrenia in high- and low-exposure groups. Where
significant differences were found, odds ratios (ORs)
were calculated.
Results
One hundred forty-seven high-risk and 36 healthy control
subjects had usable scans. For the vast majority of indi-
viduals, full information on past and present use of each
of the 3 substances of primary interest was available.
However, information on alcohol use was not available
for 7 high-risk subjects, cannabis use for 5, and tobacco
use for 10. Demographics, organized by level of use of
each of the 3 substances, are shown for high-risk subjects
in table 1. There is a (nonsignificant) trend for more
males in the highest exposure groups to both cannabis
and alcohol. There is also a significant difference in
age across the alcohol exposure groups, occasional users
tending to be younger. Additionally, there is a significant
difference in IQ across the tobacco exposure groups, the
heaviest smokers having the lowest IQ. For demographic/
drug use data in the control subjects, see supplementary
information.
Some high-risk subjects had a history of use of illicit
drugs other than cannabis. In only 3 subjects, with a his-
tory of opiate addiction, did level of past use constitute
dependence. Data on levels of use of cocaine, ecstasy,
amphetamines, and LSD are given in table 2.
Dose-Response Relationships
Structures with significant or near-significant relation-
ships between level of exposure to a substance and raw
volume in high-risk subjects are shown in table 3. Level
of alcohol consumption correlated significantly and pos-
itively with volume of the left and right lateral ventricles
(r = 0.192, P = .023, and r = 0.174, P = .005, respectively,
right lateral ventricle association shown graphically in
figure 1) and third ventricle (r = 0.183, P = .031).
Conversely, the level of alcohol consumption showed
a negative correlation with volume of the left and right
prefrontal lobes (r = 0.194, P = .022, and r = 0.166,
P = .049, respectively).
Level of cannabis use also correlated significantly and
positively with volume of the left and right lateral
ventricles (r = 0.208, P = .013, and r = 0.226, P = .007,
respectively) and third ventricle (r = 0.271, P = .001, as-
sociation shown graphically in figure 2). No significant
associations were found between tobacco use and
volumes of any of the structures of interest. The associ-
ations between substance use and structure volumes
outlined above were not apparent in the control group
(see supplementary information); though power to detect
such an association was admittedly lower, it was absent
Table2. HighestLevelsofUseofCocaine,Ecstasy,Amphetamines,
and LSD by the High-Risk Subjects
Drug
Level of Use: N (% of All High-Risk
Subjects With That Level of Use)
Never Isolated Repeated Frequent
Cocaine 140 (94.6) 0 2 (1.4) 0
Ecstasy 111 (75.0) 9 (6.1) 9 (6.1) 13 (8.8)
Amphetamine 96 (64.9) 21 (14.2) 13 (8.8) 12 (8.1)
LSD 103 (69.6) 14 (9.5) 14 (9.5) 11 (7.4)
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even at trend level. Additionally, on application of
Fisher’s Z test, there were significant interactions
between group membership and the structural conse-
quences of both alcohol and cannabis use. For alcohol,
this was significant in the right prefrontal lobe (Z =2.5,
P = .02) and third ventricle (Z = 3.45, P = <.001), while
for cannabis it was significant in the third ventricle (Z =
3.05, P = .002).
A striking feature of alcohol structure volume/expo-
sure relationships is the existence of a ‘‘J-shaped curve’’;
it seems that despite a clear tendency for a history of
greater alcohol consumption to be associated with larger
ventricular volume, third, fourth, and lateral ventricular
volumes in lifetime abstainers are greater than in those
with a history of occasional use (eg, figure 1). A comple-
mentary relationship is seen in the frontal lobes. This pat-
tern is not seen with tobacco and cannabis (eg, figure 2).
Multiple Regression Analysis
Multiple regression analyses were performed for the
lateral and third ventricles and the frontal lobes. Output
from these analyses is shown in table 4. With a single
exception (discussed below), the inclusion of IQ as an
additional factor in the model did not significantly alter
the results. Several findings are particularly noteworthy.
First, as expected from the dose-response analysis above,
level of alcohol consumption was a significant predictor
of both right and left ventricular volumes. As well as
higher levels of alcohol consumption being positively cor-
related with ventricular volume however, even relatively
modest consumption of alcohol (at levels within govern-
ment recommendations) was correlated with ventricular
enlargement. Interestingly, lifetime abstinence also posi-
tively correlated with lateral ventricle volume.
Table 3. Mean (SD) Volumes (in Cubic Centimeters) of Regions of Interest in High-Risk Subjects With Histories of Increasing Exposure to
Alcohol, Cannabis, and Tobacco
Brain Region
Level of Exposure to Alcohol
Teetotal Occasional Regular Exceed Safe Limits Dependent Correlation Analysis
Whole-brain volume 1334.48 (90.99) 1384.96 (118.75) 1326.41 (136.61) 1324.84 (125.59) 1391.75 (66.98) r = 0.062, P = .465
Left lateral ventricle 4.97 (2.77) 2.89 (2.00) 4.07 (2.20) 5.37 (4.12) 7.06 (8.78) r = 0.192, P = .023
Right lateral ventricle 3.92 (1.70) 2.75 (0.77) 3.78 (2.74) 4.79 (3.44) 7.31 (8.89) r = 0.174, P = .005
Third ventricle 0.38 (0.21) 0.29 (0.14) 0.39 (0.24) 0.47 (0.29) 0.50 (0.42) r = 0.183, P = .031
Left frontal lobe 77.6 (7.26) 81.51 (14.18) 75.00 (1.12) 72.15 (10.47) 78.38 (10.32) r = 0.194, P = .022
Right frontal lobe 78.65 (7.79) 84.65 (1.25) 79.31 (13.40) 75.76 (12.13) 79.84 (11.19) r = 0.166, P = .049
Level of Exposure to Cannabis
Nil Isolated Regular Frequent Most Days Correlation Analysis
Whole-brain volume 1327.04 (135.51) 1341.76 (132.33) 1349.0 (139.26) 1317.06 (81.63) 1387.49 (109.09) r = 0.129, P = .126
Left lateral ventricle 3.45 (2.21) 4.78 (3.11) 4.52 (3.20) 4.51 (4.00) 5.83 (5.70) r = 0.208, P = .013
Right lateral ventricle 3.08 (1.81) 4.44 (4.09) 4.19 (2.53) 4.30 (2.63) 5.23 (5.70) r = 0.226, P = .007
Third ventricle 0.31 (0.19) 0.34 (0.18) 0.45 (0.32) 0.53 (0.25) 0.47 (0.31) r = 0.271, P = .001
Left frontal lobe 76.94 (12.37) 72.31 (13.46) 75.67 (11.59) 76.58 (10.40) 78.70 (10.77) r = 0.044, P = .603
Right frontal lobe 79.44 (12.52) 77.60 (14.68) 79.52 (12.92) 79.97 (10.29) 81.38 (12.57) r = 0.058, P = .494
Level of Exposure to Tobacco
Smoking Nil 0–10 10–20 20þ Correlation Analysis
Whole-brain volume 1357.37 (135.56) 1332.05 (121.08) 1319.07 (124.60) 1352.07 (109.29) r = 0.062, P = .173
Left lateral ventricle 4.36 (2.83) 4.19 (3.11) 4.32 (2.47) 6.94 (7.83) r = 0.040, P = .639
Right lateral ventricle 3.81 (2.68) 4.07 (2.87) 4.01 (3.00) 6.04 (7.80) r = 0.079, P = .361
Third ventricle 0.37 (0.27) 0.42 (0.26) 0.40 (0.15) 0.49 (0.35) r = 0.142, P = .099
Left frontal lobe 77.33 (11.58) 75.81 (12.55) 73.34 (11.96) 75.80 (12.47) r = 0.146, P = .089
Right frontal lobe 80.80 (12.37) 80.63 (11.84) 76.04 (15.77) 75.34 (11.29) r = 0.151, P = .079
Note: Data are displayed only for the whole brain and those brain regions in which a significant correlation was observed between
volume and level of exposure to at least one substance.
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Alcohol use exceeding UK government recommenda-
tions (more than 14 units/wk for women or 21 units/wk
for men) correlated with reduced left frontal lobe volume.
This correlation was significant on the right side only
with inclusion of IQ in the model (R2 = 0.54, P =
.049). No level of alcohol consumption was correlated
with third ventricle volume (despite the strong dose-re-
sponse relationship).
Third ventricular volume did however correlate posi-
tively with frequent use of cannabis. Left ventricular
volume also correlated positively with use of cannabis
most days. Though isolated use of cannabis correlated
negatively with volume of the left frontal lobe, this
was not within the context of a dose-response relation-
ship. Tobacco consumption of more than 20 cigarettes
a day correlated negatively with volume of the right fron-
tal lobe; again the dose-response relationship between
tobacco use and volume of the right frontal lobe had
not reached significance.
Rerunning the regression analysis excluding the 3 sub-
jects with a history of opiate dependence did not alter the
above findings. However, rerunning the regression anal-
ysis with inclusion of highest use of amphetamines,
ecstasy, and LSD as additional regression blocks did. Al-
though alcohol use exceeding safe recommendations
remained a significant predictor of left lateral ventricle
and left frontal lobe volumes, it was no longer a signifi-
cant predictor of right lateral ventricle volume. Frequent
cannabis use remained a significant predictor of third
ventricular volume but not left lateral ventricle volume.
Most notably, however, in this expanded regression
model, a history of frequent (highest level of use greater
than or equal to monthly) and repeated (highest level of
use several times a year) amphetamine use was predictor
of increased right and left lateral ventricular volume (R2 =
0.125, P = .005, and R2 = 0.226, P = .011, respectively),
and repeated use of ecstasy was a predictor of increased
left lateral ventricle volume (R2 = 0.226, P = .011).
Despite the dose-response relationships between alco-
hol and cannabis and structure volumes, it was not
always the highest drug exposure level that came out
of the regression model as being significant predictors.
For this reason, the regression analysis was repeated,
combining the 2 highest exposure groups to each drug
to create a single dummy variable representing all sub-
jects with a history of substantial exposure to either
substance. The combined cannabis exposure category
correlated significantly with third ventricular volume,
this being the case both with and without the inclusion
of other illicit drugs in the regression model. Similarly
on combining the 2 highest alcohol exposure groups,
the resulting variable correlated significantly with left
and right lateral ventricular and left frontal lobe volume.
Risk of Developing Schizophrenia
None of the control subjects developed schizophrenia. The
proportion of high-risk subjects developing schizophrenia
was greater in those with a history of alcohol dependence
than subjects with all other levels of alcohol exposure com-
bined (P = .017, OR = 6.35; 95% confidence interval [CI] =
1.53–26.26). Similarly, when all subjects with cannabis ex-
posure greater than isolated use were compared with those
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Fig. 1.Bar Graph Illustrating Increased Volume of the Right Lateral
Ventricle (SE) in Association With Increasing Levels of Exposure to
Alcohol.
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Fig. 2. Bar Graph Illustrating Increased Volume of the Third
Ventricle (SE) in Association With Increasing Levels of Exposure to
Cannabis.
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below this cutoff, the former had an elevated rate of de-
veloping schizophrenia (P = .029, OR = 3.18; 95% CI =
1.08–9.36). Use of ecstasy and amphetamines did not pre-
dict development of schizophrenia. Given the lower num-
bers of subjects exposed to these drugs however, this may
be attributable to a lack of power.
Discussion
These are the first findings to demonstrate that within
a population at high risk of schizophrenia for genetic rea-
sons, but clinically well, those who abuse alcohol and/or
cannabis have structural imaging findings distinguishing
them from those who do not. Results from supplemen-
tary regression analysis suggest that use of amphetamines
and ecstasy by this population is also associated with
structural abnormalities. Additionally, both alcohol
dependence and regular cannabis use were associated
with the subsequent development of schizophrenia.
Use of these substances by people not at elevated risk
of schizophrenia was not associated with comparable im-
aging or clinical findings. We believe that the most likely
explanation for these findings is that people at high risk
of schizophrenia are more vulnerable to the effects of
these substances on the brain, but alternative explana-
tions will also be considered.
Self-medication
Though increasingly questioned (eg, by Smit et al32 and
Moore et al8 in relation to cannabis; and Drake and
Mueser33 in relation to alcohol), the idea that the associ-
ation between substance misuse and schizophrenia is
driven by self-medication for psychotic symptoms
remains pervasive.34 For self-medication to be a feasible
explanation for the current findings, it would require that
those with greater structural abnormalities were more
unwell and consumed more substances. Individuals in
this study did not have schizophrenia at the time of as-
sessment. Though many had experienced partial or tran-
sient psychotic symptoms, these were not related to brain
structural abnormalities.29 Self-medication is thus not
a tenable explanation for the associations observed in
this study. Additionally, the fact that structural abnor-
malities are detectable in association with substance
misuse in a still well population provides important
insights that can be extrapolated more generally: Brain
abnormalities potentially precipitated by substance
misuse are detectable prior to the development of illness.
Brain Structural Abnormalities Predispose to Substance
Misuse
A potential explanation for the observed association
between brain structural abnormalities and substance
misuse is that, independent of any associations with
schizophrenia, these abnormalities predispose to sub-
stance misuse. The compatibility of this explanation
with Chambers’ theory that cortical and hippocampal
dysfunctions in schizophrenia are responsible for the
greater reinforcing properties of drugs of misuse (and
hence development of drug problems) in this population
Table 4. Association of Variables of Interest With Regional Brain Volumes as Determined by the Primary Regression Analysis of Data
From People at High Risk of Schizophrenia
Dependent Variable Independent Variables b t (df) P Value
Adjusted R2
(Complete Model)
Impact of Including
IQ in Model
Left lateral ventricle Teetotal .23 2.59 (134) .011 0.11 Dependent use becomes
significant (t = 1.85, P = .066)Regular use of alcohol .21 2.06 (134) .042
Exceed safe limits of alcohol .33 3.32 (134) .001
Use of cannabis most days .20 2.31 (134) .022
Right lateral ventricle Whole-brain volume .26 3.19 (134) .002 0.14 Nil
Teetotal .19 2.13 (134) .035
Regular use of alcohol .26 2.34 (134) .021
Exceed safe limits of alcohol .40 3.74 (134) <.001
Alcohol dependence .29 3.20 (134) .002
Left frontal lobe Whole-brain volume .69 12.00 (134) <.001 0.58 Nil
Exceed safe limits of alcohol .12 2.18 (134) .031
Isolated use of cannabis .13 2.31 (134) .023
Age (y) .15 2.64 (134) .009
Right frontal lobe Whole-brain volume .67 11.1 (134) <.001 0.54 Exceed safe limits of alcohol
becomes significant
(t = 1.99, P = .049)
Exceed safe limits of alcohol .10 1.6 (134) .106
>20 cigarettes a day .13 2.2 (134) .032
Age (y) .14 2.3 (134) .020
Third ventricle Frequent use of cannabis .20 2.6 (134) .012 0.15 Nil
Gender .33 4.1 (134) <.001
Age (y) .15 1.9 (134) .065
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is evident.35 Given the cross-sectional nature of this
imaging data, we cannot here address this model as an
explanation for the observed findings. When considered
together with longitudinal data demonstrating the pro-
gressive nature of brain structural abnormalities with
ongoing alcohol use however,18 this explanation is again
untenable as a complete model. Though structural abnor-
malities may well predispose to substance misuse, this is
clearly not the whole story; it is indeed the case that
alcohol misuse does impact on brain structure.
The Observed Findings Are an Expected Consequence of
Substance Use
This hinges on the structural abnormalities observed
being a ‘‘normal’’ consequence of the reported levels of
drug use. Studies identifying the characteristic structural
abnormalities associated with alcoholism were discussed
in the ‘‘Introduction’’; these were generally undertaken in
subjects much older than the study population, with
a long history of very heavy alcohol use. Structural ab-
normalities identified in younger alcoholics have been
much more subtle. The only significant findings in
a case-control comparison of alcohol-dependent and
light-drinking men with a mean age of 30 years were
reduced cortical gray matter in the prefrontal cortex.12
A few studies have investigated structural imaging find-
ings consequent to alcohol abuse/dependence in late
adolescence. These initially reported volume reductions
in the hippocampus, but not in other regions, (including
the lateral ventricles).36 More recently, reduced prefron-
tal cortex volume has also been reported,37 though a sub-
sequent study identified this only in female subjects.38
The subjects in the current study have an average age of
21 years; none have been treated for alcohol dependence,
and few of even the heaviest users have consumed total
quantities of alcohol even approaching that in the studies
outlined above. Thus, though subtle structural changes,
possibly including a degree of frontal lobe volume loss,
may be observable in ‘‘uncomplicated’’ alcoholism in
this age range, the gross structural abnormalities we
observed would not be expected in a healthy population.
As discussed above, in the case of cannabis, there is little
evidence for brain structural abnormalities even in chronic
users.16,17 Studies comparing ecstasy users to control sub-
jects also fail to identify notable volumetric structural ab-
normalities.39 More marked abnormalities have been
reported in association with methamphetamine use. Spe-
cifically, in a cross-sectional study comparing subjects with
a history of long-standing methamphetamine dependence
to nonusing control subjects, hippocampal and right-sided
cingulate gray matter loss accompanied by right frontal
ventricular enlargement were reported.40 Reduced cortical
gray matter has been reported in several subsequent
reports, together with enlargement of the corpus striatum
(reviewed in Berman et al41).
In summary, though there is evidence for gross volu-
metric abnormalities in individuals with long-standing,
heavy use of amphetamines, there is no evidence for
such sequelae in otherwise healthy individuals following
even substantial use of the other illicit drugs discussed.
None of the subjects in this study met criteria for depen-
dence on amphetamines or ecstasy, and use was at mark-
edly lower levels than in the studies outlined above. It
thus again seems highly unlikely that structural abnor-
malities of the magnitude observed in the high-risk pop-
ulation can be regarded as an expected consequence of
reported levels of substance use.
This is further supported by the absence of any com-
parable relationship between volumetric measurements
and either alcohol or illicit substance use in the control
group. Though numbers in this group are admittedly
small, raising the possibility that it is underpowered to
detect such relationships, there is no suggestion that
they are even present at trend level. Indeed, Fischer Z
test (which accounts for the relative size of each group)
demonstrated a significant difference between high-risk
and control subjects in the effect of alcohol on the right
prefrontal lobe and cannabis on the third ventricle.
People atElevatedRisk of SchizophreniaAreParticularly
Vulnerable to the Brain Structural Consequences of
Substance Use
As discussed above, the brain structural abnormalities
observed in this population in association with use of
alcohol, cannabis, amphetamine, and ecstasy are all of
greater magnitude than would be expected in healthy
individuals with a comparable level of exposure. This
is in keeping with previous evidence that brain volume
loss is more pronounced in individuals with established
schizophrenia who use either alcohol or cannabis,20,42
findings that suggested that individuals with schizophre-
nia have a particular sensitivity to brain volume loss on
exposure to these substances. The current study builds on
this work, being the first to provide structural imaging
evidence that such a process may occur in a population
at high risk of schizophrenia but currently clinically well.
This provides biologically plausible evidence of how use
of these substances may be contributing to the etiology of
schizophrenia and clearly underlines the potential
hazards of a high-risk population using them.
Cannabis and Alcohol in the Etiology of Schizophrenia
The proposal that cannabis may be contributing to the
etiology of schizophrenia is not new, and the dangers
of its use by people vulnerable to psychosis have previ-
ously been emphasized.6 These risks are reflected in
this cohort, cannabis use again being associated with
an increased rate of development of schizophrenia.
More controversially, however, follow-up of this popula-
tion also revealed a markedly elevated rate of
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schizophrenia in subjects with a history of alcohol depen-
dence. Taken together with the pronounced structural
abnormalities associated with alcohol consumption in
this group, this raises the possibility that alcohol con-
sumption could itself be interacting with vulnerability
factors for schizophrenia to increase some individuals’
risk of developing the condition.
Though overshadowed by cannabis research in recent
years, consideration of the possibility that alcohol use
may play a role in the development of schizophrenia is
not entirely novel. Indeed, such speculation has long
been supported by the observation that chronic alcohol
consumption may occasionally result in the generally self-
limiting psychotic disorder known as alcoholic hallucino-
sis. In this condition, auditory hallucinations and
delusions of reference and persecution are prominent,
though other schizophrenic symptoms such as thought
disorder and passivity are generally absent.27 Though
this indicates that alcohol consumption can result in psy-
chotic symptoms, the fact that family and genetic studies
failed to demonstrate a greater prevalence of schizophre-
nia in relatives of patients with alcoholic hallucinosis led
to genetic predisposition for the 2 conditions being
regarded as independent.43 This appeared to reduce inter-
est in the potential of alcoholic hallucinosis to shed light
on the pathophysiology of schizophrenia, and there has
been comparatively little research into the condition in
recent years. There seems no good reason however
that the results of these family studies should preclude
the possibility that alcohol can potentially play a role
in the etiology of schizophrenia.
A role for alcohol (and other substances under inves-
tigation in this study) in the development of schizophre-
nia is easily conceptualized within the framework of the
stress vulnerability theory of schizophrenia.44 Within this
model, alcohol interacts with other risk factors for
schizophrenia to increase an individual’s vulnerability
to developing the condition. In this context, the finding
that those with alcoholic hallucinosis have no family his-
tory of schizophrenia is not necessarily dissonant. It may
be expected that as a consequence of heavy alcohol con-
sumption some individuals (likely those with fewer sus-
ceptibility genes for schizophrenia) develop alcoholic
hallucinosis, generally a temporary and self-limiting phe-
nomena; those with a greater predisposition for schizo-
phrenia, however, on exposure to similar or even lower
levels of alcohol, may go on to develop a condition indis-
tinguishable from classical schizophrenia.45 Given that
they were selected on the basis of genetic loading for
schizophrenia, the subjects in this study are heavily
weighted toward the latter group. As would be expected
from this theory, they exhibit prominent structural brain
abnormalities in association with a history of heavy
alcohol consumption, and alcohol dependence is associ-
ated with a significantly elevated risk of developing
schizophrenia.
Relevance of Other Findings From the EHRS
Previous findings from the EHRS have shown that those
subjects who develop schizophrenia exhibit significantly
greater losses of gray matter density than those who
remain well,46 these measures having utility in predicting
schizophrenia.47 The current findings add to this, demon-
strating that in individuals at elevated genetic risk of
schizophrenia exposure to a variety of psychoactive sub-
stances is associated with dramatic brain structural ab-
normalities. Further analysis of the dataset, in
particular investigating the relationship between these
risk factors and longitudinal brain changes, is required.
The current findings do however suggest that the devel-
oping brains of individuals at elevated genetic risk of
schizophrenia are exquisitely vulnerable to the effects
of a wide range of drugs of abuse. Given the findings
of Job et al,46,47 it is most likely that this volume loss
is occurring in gray matter, the very structure shown
to be particularly susceptible to the effects of alcohol
and cannabis in dual diagnosis studies of schizophre-
nia.20,42 The consequences of this brain tissue loss in
adolescents at high risk of developing schizophrenia ap-
pear to be profound, this being reflected in the elevated
risk of psychosis in those individuals with a history of
either alcohol dependence or substantial exposure of
cannabis.
Though the findings detailed above do seem robust,
a number of points require further clarification. First, as-
certainment of drug use relied on self-report of partici-
pants, which may not be reliable. While an objective
method to determine history of drug use would have
been desirable, unfortunately no appropriate tool exists.
Given that we were interested in lifetime history of drug
use, drug testing would have added little to the study.
Furthermore, self-report of drug use is in fact a reliable
tool in the research context.48
For some substances, the level of use that significantly
correlated with structure volume in the regression model
was not the highest level of exposure. For example,
‘‘excessive use’’ of alcohol rather than ‘‘dependence’’ pos-
itively correlated with right ventricular volume, despite
mean ventricular volume in the latter group being greater
than the former (4.79cm3 and 7.31cm3, respectively). In
the case of alcohol exposure, this is explained by the num-
ber of subjects in the highest exposure group being rela-
tively few compared with the excessive use category. This
is not so for cannabis exposure however, there being more
subjects in the ‘‘most days’’ than ‘‘frequent’’ category, yet
the latter emerging as having a significant correlation
with third ventricular volume. Given this, the latter anal-
ysis was repeated combining these 2 exposure groups to
create a single dummy variable representing all subjects
with a history of substantial exposure to cannabis. The
combined exposure category correlated significantly
with third ventricular volume, this being the case both
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with and without the inclusion of other illicit drugs in the
regression model. This reinforces the veracity of the as-
sociation between cannabis exposure and third
ventricular volume.
The majority of findings from the regression analysis
were robust to inclusion of past use of amphetamines, ec-
stasy, and LSD as additional regression blocks. That
heavy use of alcohol was no longer a significant predictor
of right lateral ventricular volume and frequent use of
cannabis no longer a significant predictor of left ventric-
ular volume are most likely due to the loss of power
resulting from the inclusion of additional factors.
Data on control subjects have been included for com-
pleteness. Given their small numbers we have not focused
on them in detail, but, as discussed above, the absence of
structural associations comparable to those observed in
high-risk subjects is in keeping with findings from other
studies. The finding of decreased third ventricular volume
with increasing history of alcohol exposure is notable
however and requires further comment. This was unex-
pected and may not be reproducible in a larger sample
of control subjects. It is notable however that noncon-
sumption of alcohol is very unusual in Scotland,49 and
as such teetotal individuals may possess characteristics
atypical of the general population. As such, it is conceiv-
able that some unidentified confounding factor and/or
factors are driving this unexpected relationship. Such fac-
tors may also be of relevance in understanding the com-
parable trend toward third ventricular volume reduction
observed in this group in association with cannabis con-
sumption.
It is the case that the current findings offer little insight
into the processes occurring at a cellular or receptor level
that result in the observed effects. The particular impact
of cannabis on regions surrounding the third ventricle
may offer some clues as to the circuits involved in medi-
ating the propsychotic effects of this drug, but the struc-
tural consequences of the other substances investigated
generally seem diffuse. Though speculative, it seems to
us most likely that the genesis of these abnormalities
involves an interaction between substance misuse and ge-
netic risk to result in abnormalities of maturational pro-
cesses. Clearly, however, considerable further work is
required to clarify the nature of these processes and
the mechanisms by which they are deranged by exposure
to drugs of abuse.
While acknowledging the points above, it does there-
fore seem to be the case that a history of heavy use of
alcohol in this high-risk population is indeed associated
with lateral ventricular enlargement and frontal lobe vol-
ume loss; a history of frequent use of cannabis is associ-
ated with third ventricular enlargement; and repeated/
frequent use of amphetamines and ecstasy is associated
with increased lateral ventricular volume. These findings
have major implications, particularly when viewed in
combination with the elevated rate of development of
schizophrenia associated with illicit drug and alcohol
use that we also report. They not only add to our under-
standing of the pathogenesis of schizophrenia but also
underline the potential hazards of even relatively modest
recreational drug use by adolescent subjects at genetic
risk of schizophrenia.
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